作者
Zeeshan Javed, Maria Papageorgiou, Harshal Deshmukh, Alan S Rigby, Unaiza Qamar, Jehangir Abbas, Amer Y Khan, Eric S Kilpatrick, Stephen L Atkin, Thozhukat Sathyapalan
发表日期
2019/6
期刊
Clinical endocrinology
卷号
90
期号
6
页码范围
805-813
简介
Background
Empagliflozin is a sodium‐glucose‐cotransporter‐2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type‐2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS.
Materials and methods
A randomized open‐label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters.
Results
Univariate analysis showed significant differences in weight (empagliflozin: −1.4 …
学术搜索中的文章
Z Javed, M Papageorgiou, H Deshmukh, AS Rigby… - Clinical endocrinology, 2019